Description
Release form
Lyophilisate for solution for infusion.
Packing
1 fl.
Pharmacological action
Resorb has an effect that inhibits bone resorption.
Indications
osteolytic, osteoblastic and mixed bone metastases of solid tumors
osteolytic lesions in multiple myeloma
hypercalcemia caused by a malignant tumor.
Special instructions
Ensure that the patient is adequately hydrated before the infusion. If necessary, it is recommended that physiological saline be administered before, in parallel, or after infusion of zoledronic acid. Overhydration of the patient should be avoided due to the risk of complications from the cardiovascular system. Before the infusion, the patient should be adequately hydrated. If necessary, it is recommended that physiological saline be administered before, in parallel, or after infusion of zoledronic acid. Overhydration of the patient should be avoided due to the risk of complications from the cardiovascular system.
Composition
1 vial contains zoledronic acid monohydrate 4.26 mg.
Dosage and administration
Resorb is administered iv, drip for at least 15 minutes. The dosage regimen is set individually. The recommended dose is 4 mg every 3-4 weeks.
Side effects
Adverse reactions are listed below in organs and systems with an indication of their frequency of occurrence. Frequency criteria: very often? 1/10 often? 1/100 –
From the hemopoietic organs: often anemia, sometimes thrombocytopenia, leukopenia is rarely – pancytopenia.
From the nervous system: often – headache sometimes – dizziness, paresthesia, taste disturbances, hypesthesia, hyperesthesia, tremors, anxiety, sleep disorders rarely – confusion.
From the side of the organs of vision: often – conjunctivitis sometimes – blurring of the vision is very rare – uveitis, episiscleritis.
From the gastrointestinal tract: often – nausea, vomiting, anorexia, sometimes – diarrhea, constipation, abdominal pain, dyspepsia, stomatitis, dry mouth.
From the respiratory system: sometimes – shortness of breath, cough.
On the part of the skin and skin appendages: sometimes – itching, rash (including erythematous and macular), excessive sweating.
From the musculoskeletal system: often – bone pain, myalgia, arthralgia, generalized pain, sometimes – muscle cramps.
From the cardiovascular system: sometimes – a marked increase or decrease in blood pressure rarely – bradycardia.
From the urinary system: often – impaired renal function, sometimes – acute renal failure, hematuria, proteinuria.
On the part of the immune system: sometimes – hypersensitivity reactions rarely – angioedema.
Drug interactions
Solutions containing calcium, in particular Ringer’s solution, cannot be used as solvents.
With the simultaneous use of anticancer drugs, diuretics, antibiotics, analgesics, clinically significant interactions were not observed.
Bisphosphonates and aminoglycosides have a unidirectional effect on the concentration of calcium in the blood serum, therefore, when administered simultaneously, the risk of hypocalcemia and hypomagnesemia increases.
Caution is necessary while using zoledronic acid with drugs that potentially have nephrotoxic effects.
In patients with multiple myeloma, an increased risk of developing renal dysfunction with the intravenous administration of bisphosphonates in combination with thalidomide is possible.
The drug should not be mixed with other medicines.
Overdose
In case of accidental overdose of Resorba, the patient should be constantly monitored.
In the case of hypocalcemia, accompanied by clinical manifestations, an infusion of calcium gluconate is indicated.
Storage conditions
In a dry place, at a temperature not exceeding 25 ° C.
Active ingredient
Solendronic acid
Dispensing conditions from drugstores p1414 pharmacy s14l14 pharmacy14
Prescription
Dosage form
solution for infusions
